Published by Benjamin Chiou on 27th June 2024
(Sharecast News) - Shares in biopharma giant GSK tumbled on Thursday after a ruling by a US health agency narrowed usage recommendations for all respiratory syncytial virus (RSV) vaccines, restricting the addressable market for the company's Arexvy product.
URL: http://www.digitallook.com/dl/news/story/34391529/...